Abstract: A tissue factor (TF)-targeted antibody-drug conjugate (ADC) and a method for preparing the ADC. The ADC is capable of binding to TF antigen with high specificity, and has high affinity, low immunogenicity, high cytotoxicity, and significant anti-tumor activity.
Type:
Grant
Filed:
June 9, 2017
Date of Patent:
December 27, 2022
Assignees:
FUDAN UNIVERSITY, SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES, SHANGHAI MIRACOGEN INC.
Inventors:
Ke Yu, Jingkang Shen, Tao Meng, Lanping Ma, Xuesai Zhang, Qingrou Li, Qing Lin
Abstract: The present invention relates to an antibody-drug conjugate, in particular, to an antibody-drug conjugate targeting an epidermal growth factor receptor. The present invention also relates to a composition comprising the antibody-drug conjugate, and use of the antibody-drug conjugate in manufacture of a medicament for the prophylaxis and/or treatment of a disease associated with epidermal growth factor receptor, in particular in manufacture of a medicament for prophylaxis and/or treatment of colon cancer, rectal cancer, head and neck cancer, lung cancer, ovarian cancer, cervical cancer, bladder cancer and esophageal cancer. The antibody-drug conjugate of the invention has a good inhibition activity on tumor cell growth both in vivo and in vitro, and has low toxicity, and thus has a good application prospect.
Abstract: The present invention provides a tissue factor (TF) monoclonal antibody and a preparation method therefor. The monoclonal antibody provided by the present invention can specifically bind with a TF antigen, has high affinity and low immunogenicity, and has the activity of resisting tumors and the like.
Type:
Grant
Filed:
February 20, 2017
Date of Patent:
June 9, 2020
Assignees:
Fudan University, Shanghai Miracogen Inc.
Inventors:
Ke Yu, Xuesai Zhang, Qing Lin, Qingrou Li